Product Images Levetiracetam

This appears to be a table of percentages with some numerical values, but it is not clear what the table represents without additional context.*

This appears to be a statistical analysis report or a medical study report. It provides results of a study that involved two groups of participants, one receiving immediate-release levetiracetam and the other receiving a placebo. The text also contains percentage values, a pound sign, and some symbols such as * and =. The symbols seem to be used to signify significance levels. Overall, without more information, it is unclear what the study was about or what its findings were.*

The text shows a graph with the percentage of patients on the y-axis and certain values on the x-axis. There are two groups portrayed, one represented by 14.4% and the other by 39.4%. The first group is labelled as placebo with a sample size of 104, and there is a symbol indicating there is a statistically significant difference compared to the second group, which is labelled as Immediatomrelease Levetiracetam with a sample size of 180 taking 3000 mg/day.*

This appears to be a graph that shows the percentage of patients in a study who experienced certain effects or outcomes based on the medication they were taking: a Placebo (N-97) and an Immediaterelease levetiracetam (N=101). However, it is difficult to discern the exact details and meaning of the data without more context.*

This is a medication called Levetiracetam, administrated through its extended-release tablets each containing 750 mg USP. The recommended dosage and details on storage are provided on the accompanying prescribing information. Patients are required to receive the medication guide. Manufactured by Lupin Limited in Goa, India, for Lupin Pharmaceuticals in Baltimore, Maryland, USA.*